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Natural product biosynthesis is inherently linked with the primary metabolism in terms of providing
precursors and co-factors. Thus, even though it is important to improve the performance of natural
product biosynthetic enzymes in building eﬃcient cell factories, it is equally important to engineer the
central carbon metabolism, such that this is adjusted to meet the biosynthetic demand of the desired
product.1 Introduction
Over the last 70 years natural products have served as a rich
source of pharmaceuticals, and as these chemicals oen can
provide novel chemical scaﬀolds enabling new bioactive prop-
erties, there is much interest in developing platforms for eﬃ-
cient production of them. Traditionally, bioactive molecules
have been produced by the cell factory that naturally produces
the molecule, e.g. microorganism or plant, and in many cases
breeding has been used to improve the production level. This is
best illustrated in the production of penicillin, where strain
improvement programs have resulted in more than 10 000
times improvement of the production level by the fungus
Penicillium chrysogenum. However, with the introduction of
genetic engineering, and more recently of synthetic biology
tools that has enabled eﬃcient genome editing, it has become
possible to use a more directed approach to strain improve-
ment. Moreover, it has been possible to express biosynthetic
pathways in heterologous hosts, which has enabled decoupling
the choice of host (or chassis) from the biosynthetic pathway of
interest. Furthermore, this has enabled generation of so-called
platform cell factories1 that are optimized for producing a class
of compounds. An excellent early example of this was demon-
strated by the Dutch company DSM, that recruited one of their
very eﬃcient penicillin producing strains for production of
adipoyl-7-aminodeacetoxycephalosporanic acid (adipoyl-7-
ADCA) by expressing a heterologous expandase that could
convert adipoyl-6-aminopenicillanic acid (adipoyl-6-APA) into
adipoyl-7-ADCA. Adipoyl-7-ADCA is an important precursor for
chemical synthesis of cephalexin, a widely used broad-spectrum
antibiotics.DK2200 Copenhagen, Denmark
Engineering, Chalmers University of
osustainability, Technical University of
-mail: jni@novo.dk
hemistry 2019In more recent years this has been taken much further,
resulting in refactoring of complex biosynthetic pathways in
heterologous hosts, as illustrated by the recent reconstruction
of a 23 step enzymatic pathway for production of hydrocodone
in Saccharomyces cerevisiae.2 Here there has been focus on a few
diﬀerent cell factory platforms for production of natural prod-
ucts: (1) the yeast S. cerevisiae, which is benecial as it is easy to
genetically engineer and enables expression of plant P450
enzymes; (2) the Gram-negative bacterium Escherichia coli,
which allows for high-level expression of heterologous enzymes
and has a exible metabolism that can adjust easily to heter-
ologous pathways; (3) the Gram-positive actinomycetes Strep-
tomyces coelicolor, which produces several natural products and
hence has the capacity to support production of many other
natural products, in particular gene clusters from other acti-
nomycetes. However, the list of cell factory platforms is
expanding, andmany would probably add a lamentous fungus
to this list, but here there is less consensus, as both P. chrys-
ogenum and various Aspergilli compete for this spot. The
advantage of using cell factory platforms is that the central
carbon metabolism can be tailored to production of a class of
molecules that use the same precursor, e.g. acetyl-CoA oen
used for polyketide synthases.
Here I will discuss some of the key points to consider when
natural product biosynthesis has to be improved in a given
microbial cell factory: (1) the central carbon metabolism as it
provides the precursors and the co-factors for natural product
biosynthesis; (2) choice of microbial cell factory; and (3) opti-
mization of the enzymes in the biosynthetic pathway in order to
avoid a proteome constraint issue.2 Link between primary and
secondary metabolism
Penicillin production by the lamentous fungus P. chrysogenum
is a good example of how primary and secondary metabolism is
closely linked. Penicillin is produced in a three-stepNat. Prod. Rep., 2019, 36, 1233–1236 | 1233
Fig. 1 Simpliﬁed illustration of how primary and secondary metabo-
lism is connected and the concept of proteome constraints. (A)
Overview of metabolism. Nutrients, e.g. glucose, are metabolized via
central carbon metabolism and hereby generates precursor metabo-
Natural Product Reports Viewpoint
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
A
pr
il 
20
19
. D
ow
nl
oa
de
d 
on
 1
2/
3/
20
19
 2
:1
6:
49
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinebiosynthetic pathway. In the rst step, the non-ribosomal
peptide synthetase (NRPS) L-a-aminoadipoyl-L-cysteinyl-D-
valine synthetase (ACVS) condenses L-a-aminoadipic acid, L-
cystein, and L-valine into the tripeptide L-a-aminoadipoyl-L-cys-
teinyl-D-valine (ACV). In the next step, isopenicillin N synthase
(IPNS) converts ACV into isopenicillin (IPN) with the use of
molecular oxygen as electron acceptor. In the nal step, the L-a-
aminoadipoyl side chain of IPN is cleaved oﬀ resulting in
formation of 6-APA that can be further converted to penicillin V
or penicillin G depending on whether the cells are fed with
phenoxyacetic acid or phenylacetic acid. Naturally, P. chrys-
ogenum produces a minute amount of penicillin, and thus only
a small amount of the three amino acids (with L-a-aminoadipic
acid being an intermediate of L-lysine biosynthesis) are used for
penicillin production. However, in connection with strain
improvement programs, where the ux towards penicillin was
signicantly improved, increasing the supply of the three amino
acids was essential. Furthermore, as cysteine biosynthesis
requires reduction of sulfate provided in the medium to
hydrogen sulfate, penicillin biosynthesis indirectly requires
large amounts of NADPH. Thus, whereas the rst strain
improvement initiatives (all done by classical mutagenesis and
screening) most likely resulted in improvement of the activity of
the penicillin biosynthetic enzymes as well as increased
expression through increasing the copy number of the biosyn-
thetic gene cluster, the later strain improvement eﬀorts clearly
required mutations supporting eﬃcient provision of the three
amino acids and suﬃcient NADPH. Another example is that
actinorhodin (and to some extend undecylprodigiosin)
production by S. coelicolor could be signicantly improved by
deletion of one of the isoforms of phosphofructokinase (pA2).3
From metabolic modelling it was identied that the production
of the polyketide actinorhodin requires large amounts of
NADPH, and through deletion of one of the phosphofructoki-
nase isoenzymes ux through the glycolysis was attenuated
resulting in an increased ux through the pentose phosphate
pathway. This led to increased NADPH supply for secondary
metabolite production, and hence increased production of
actinorhodin.Jens Nielsen is CEO of the Bio-
Innovation Institute, Denmark
and Professor at Chalmers
University of Technology, Swe-
den. His research is to study and
engineer metabolism. He has
supervised more than 120 PhD
students and more than 75 post
doctoral researchers. He has
published so far more than 700
papers that have been cited more
than 53 000 times (current H-
factor 113) and co-authored
several textbooks. He has founded several biotech companies. He
has received numerous Danish and international awards and is
member of nine academies in Denmark, Sweden and USA.
1234 | Nat. Prod. Rep., 2019, 36, 1233–1236At the more general level, the key links between primary and
secondary metabolism are (Fig. 1A): (1) precursor metabolites,
with acetyl-CoA being the most notable as it is used as precursor
for biosynthesis of polyketides as well as isoprenoids; (2) amino
acids, that are used as precursors for production of non-
ribosomal peptides; (3) aromatic amino acids, which are used
as precursors for avonoids and alkaloids. Many other inter-
mediates of the central metabolism can serve as precursors for
natural product biosynthesis, but those listed above represent
important ones. Besides the precursor, there is also a strong
link between central metabolism and natural product biosyn-
thesis through the requirement for redox power, oen in the
form of NADPH, and Gibbs free energy, oen in the form of
ATP. These links are very well illustrated in studies where
natural product pathways have been reconstructed in a heter-
ologous host, and in order to achieve high level production it
has been necessary to engineer central metabolism. Examples
are the production by yeast of artemisinic4 acid, farnesene5 and
resveratrol.6 Artemisinic acid is an anti-malarial drug and far-
nesene is a hydrocarbon that can be used as jet-fuel or for
synthesis of squalene. Both chemicals are derived from farnesyl-
pyrophosphate (FPP) by expressing a specic sesquiterpene
synthase, and whereas farnesene is produced directly by one
enzyme, artemisinic acid biosynthesis requires a few additionallites. These are converted into amino acids and other cellular building
blocks, but can also be used directly by secondary metabolism, e.g. by
polyketide synthetases. In secondary metabolism amino acids,
precursor metabolites (or other intracellular metabolites) are con-
verted into natural products via a series of intermediates, and this part
of metabolism is often distributed into initial biosynthetic steps and
tailoring steps. A typical example is biosynthesis of an non-ribosomal
peptide by an NRPS followed by modiﬁcations as mentioned for
penicillin biosynthesis in the text. Finally the natural products are
secreted out of the cell. (B) Illustration of the concept of proteome
constraints. The total cellular proteome has an upper bound, which for
many cell factories is even relatively constant across diﬀerent envi-
ronmental conditions. The cellular proteome can therefore be deﬁned
as allocation for diﬀerent fractions within a deﬁned box as illustrated in
the ﬁgure. The total proteome is allocated for translation, DNA
metabolism and transcription, central carbon metabolism, amino acid
metabolism, lipid biosynthesis and natural product biosynthesis (nor-
mally a small fraction). A certain part of the proteome is also allocated
to proteins with unknown function. The proteome constraints mean
that if one part of the proteome requires additional proteome mass it
has to be at the expense of proteome mass for other functions.
This journal is © The Royal Society of Chemistry 2019
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View Article Onlinebiosynthetic steps. However, for production of both chemicals it
is necessary to have eﬃcient supply of FPP, and this required
engineering of not only the mevalonate pathway leading to FPP,
but also central carbonmetabolism to ensure eﬃcient provision
of acetyl-CoA and NADPH.5 To ensure high-yields, a heterolo-
gous pathway involving phosphoketolase was expressed in
yeast.5 This pathway takes xylulose-5-phosphate, an interme-
diate of the pentose phosphate pathway, and converts it into
acetyl-phosphate and glyceraldehyde-3-phosphate. Acetyl-
phosphate can be converted directly to acetyl-CoA by another
enzyme, and hereby a new pathway for providing acetyl-CoA was
installed. For improving resveratrol biosynthesis, which is
synthesized from phenylalanine or tyrosine as well as malonyl-
CoA, it was necessary to engineer the aromatic amino acid
biosynthetic pathway to allow for high ux, but also to improve
the provision of malonyl-CoA.6 Also this pathway requires
extensive NADPH, so steps to ensure eﬃcient provision of this
co-factor also had to be considered.
3 Choice of cell factory
The second critical factor for optimizing the production of
natural products is the chose the right cell factory. This can be
very diﬃcult, but the following points should be considered: (1)
is the pathway compatible with the host, i.e. can the host deliver
the precursors required for the biosynthetic pathway and if the
pathway spans diﬀerent compartments in its endogenous host,
can this be reproduced in the heterologous host. An excellent
example of pathway compatibility with the host is the produc-
tion of adipoyl-7-ADCA mentioned earlier, as here the host
already had a very eﬃcient pathway for biosynthesis of adipoyl-
6-APA. Oen it is, however, more diﬃcult to judge, but there
some of the following points can probably assist; (2) is it easy to
engineer the cell factory that is going to host the heterologous
pathway? The answer is for sure yes for E. coli and S. cerevisiae,
but these two cell factories are not always optimal for produc-
tion of natural products. E.g. it may be better to use a Strepto-
myces species to express pathways discovered in Gram-positive
actinomycetes and a fungus to express pathways discovered in
other fungi. This is due to diﬀerences in G/C-content of the gene
clusters but also compatibility of the promoter regions. Here the
nal choice may depend on which tools are available for genetic
engineering of the host; (3) even though it can be an advantage
of expressing pathways for fungal natural products in a fungus,
there are drawbacks of this approach. Thus, most lamentous
fungi that produce natural products, contain a large number of
biosynthetic gene clusters, i.e. up to 50 clusters have been
discovered through genome-sequencing of several Penicillia.7
This means that there is a risk that enzymes from other
biosynthetic pathways are expressed in the chosen host, and
these enzymes may interfere with the heterologous biosynthetic
pathway. This holds true in particular for glycosyltransferases,
but also for many other types of so-called tailoring enzymes that
decorate the aglycone. This can of course be an advantage if one
is aiming for product diversity, but it does complicate pathway
discovery and will also complicate optimizing production of
a specic molecule. Here use of hosts that have no or limitedThis journal is © The Royal Society of Chemistry 2019secondary biosynthesis capabilities, such as E. coli and yeast,
have benets, but the trade-oﬀ is poor pathway compatibility;
(4) the ability to express functional pathway enzymes in the host
is a very important factor. In some cases this is hard to judge at
the outset, but if the pathway e.g. contains P450 enzymes it does
not makes a lot of sense to use E. coli as a host, as this class of
enzymes express poorly in bacteria, whereas they generally
express well in yeast. This is mainly due to their membrane
association, i.e. they can be expressed to function in the endo-
plasmic reticulum membrane of yeast. This, however, also
means that it is important to consider the proteome constraints
discussed below (see also Fig. 1B), as this may now apply not
only to the total proteome, but the proteome of the specic
membrane compartment where the enzyme(s) need(s) to be
expressed; and (5) is the natural product toxic to the cell factory?
This is of course a very important factor. Oen natural
producers also express a gene encoding for an enzyme or
transporter that confer resistance towards the chemical, and
this may then also be expressed in the cell factory of choice.
However, it is not always the case, and this then becomes part of
the cell factory and natural product biosynthesis compatibility
evaluation.4 Enzyme activity and ﬂux control
The third critical factor for improving natural product biosyn-
thesis is the catalytic eﬃciency of the biosynthetic enzymes.
Enzymes of secondary metabolism generally have lower kcat
values and are generally larger than enzymes of the primary
metabolism.8 This generally means that it may be hard to
increase the ux through the biosynthetic pathway leading
towards the natural product for predominantly two reasons.
First, with low kcat values of the enzymes it is generally
necessary to express these enzymes to very high levels in order
to ensure suﬃcient enzymatic capacity required for a given ux.
Even though this can easily be achieved through using strong
promoters and multi-copy expression (as has occurred naturally
in high penicillin producing strains of P. chrysogenum that
carries multiple copies of the biosynthetic gene cluster), there is
a trade-oﬀ with this approach. High-level expression of the
biosynthetic enzymes, which generally have a high molecular
weight as mentioned above, results in an increased requirement
for allocation of proteome mass to natural product biosyn-
thesis. As the cellular proteome is nite (see Fig. 1B), this means
that there have to be reduced allocation of proteome for other
cellular processes. As the majority of the proteome in a cell is
normally allocated for central metabolism and protein biosyn-
thesis, the consequence is that there is a reduction in proteome
allocated for these processes. The result is a reduction in growth
rate. It may be possible to accept this trade-oﬀ, but it is
important to keep in mind, and as it is diﬃcult to control which
part of the proteome should be “sacriced”, the trade-oﬀ may
well result in unwanted phenotypes. In order to overcome this
problem it is therefore important to quantify the kcat of the
biosynthetic enzymes and evaluate how much of the proteome
is required for supporting a certain ux through the pathway. IfNat. Prod. Rep., 2019, 36, 1233–1236 | 1235
Fig. 2 Illustration of how kcat impacts ﬂux control through a biosyn-
thetic pathway. Flux through each enzymatic step is determined by the
product of three terms: (1) kcat; (2) enzyme concentration Ei; and (3)
the concentration of substrates, products and allosteric regulators of
the enzyme, here captured in the non-speciﬁed function f(c). The sum
of enzyme concentrations have an upper value, i.e. determined by how
much proteome mass that can be allocated for this speciﬁc pathway,
and therefore it is important to distribute the enzyme mass, which can
be controlled through varying gene expression, appropriately to the
diﬀerent steps in the pathway such that ﬂux through each step is
balanced. The distribution of mass to each enzyme should clearly be
determined based on knowledge of the kcat values of each enzyme.
Natural Product Reports Viewpoint
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
A
pr
il 
20
19
. D
ow
nl
oa
de
d 
on
 1
2/
3/
20
19
 2
:1
6:
49
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinethis fraction is large it is important to focus on improving the
catalytic eﬃciency of the enzymes in the pathway.
Second, not only does the natural product pathway enzymes
generally have low kcat-values, but there may also be large
diﬀerences along the pathway (most natural product pathways
have multiple steps). This can cause large diﬀerences in ux
control along the pathway (Fig. 2), and in order to identify
whether this is a problem it is important to measure pathway
intermediates when the pathway enzymes are expressed at
diﬀerent levels. It is diﬃcult to quantify the level of ux control
along a pathway, but with the development of biosensors that
enable measurements of intracellular metabolite levels, it has
become possible to screen for large libraries of cells where the
pathway enzymes are expressed at diﬀerent levels. The issue of
ux control is particularly challenging for very long biosynthetic
pathways, but in some cases one can benet from breaking the
pathway into diﬀerent segment and then optimize ux through
each segment separately before the whole pathway is assembled.
5 Conclusions
I here argue that in connection with optimization of cell facto-
ries for production of natural products there are in particular1236 | Nat. Prod. Rep., 2019, 36, 1233–1236three aspects that needs to be considered: (1) engineering of the
central metabolism in order to ensure suﬃcient supply of
precursors and co-factors; (2) choice of cell factory; and (3)
improving the properties of the enzymes in the biosynthetic
pathway, particularly to overcome the problem of a proteome
constraint within the cell (or specic compartment where the
pathway is expressed). Having all these three aspects in mind, it
should be possible to design a strategy for developing an eﬃ-
cient cell factory for production of natural products.6 Conﬂicts of interest
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